Schlieren ZH – Memo Therapeutics AG has presented preclinical data on its drug candidate Potravitug. Accordingly, the therapeutic potential in the treatment of BKPyV infections has been demonstrated.
(CONNECT) Schlieren-based Memo Therapeutics is working on a highly effective human monoclonal antibody for the treatment of BKPyV infections. These infections are caused by the BK virus. Memo Therapeutics is developing the antibody Potravitug for the treatment of BKPyV infections in kidney transplant recipients. According to a press release, the clinical data now presented show the therapeutic potential of Potravitug.
Potravitug is thus positioned as a "potentially transformative treatment for BKPyV infections that can have devastating consequences for transplant recipients", Erik van den Berg, CEO of Memo Therapeutics, is quoted in the press release.
The Schlieren-based company will present data from a placebo-controlled Phase II clinical trial of Potravitug at the World Transplant Congress in San Francisco at the beginning of August.
Memo Therapeutics is a spin-off of the Swiss Federal Institute of Technology in Zurich and is based in the Bio-Technopark Schlieren-Zurich. ce/jh
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information